Clinical Study Number | 528.204 |
---|---|
Study Indication | Healthy |
Product | Terbogrel |
Generic Name | Terbogrel |
Lab Code | |
Clinical Phase | I |
Study Title |
Relative bioavailability and tolerability of two new different extended release capsules of 50 mg BIBV 308 SE each, versus a solution of 50 mg BIBV 308 SE administered orally twice a day for 3.5 days to healthy subjects (cross-over, open, randomised). |
Study Document | Trial synopsis 528.204 english |
Clinical Study Number | 528.22 |
---|---|
Study Indication | Healthy |
Product | Terbogrel |
Generic Name | Terbogrel |
Lab Code | |
Clinical Phase | I |
Study Title |
Relative bioavailability and tolerability of various experimental formulations of 50 mg BIBV 308 SE administered orally twice a day over 3.5 days to healthy subjects (intraindividual comparison, open, partially randomised). |
Study Document | Trial synopsis 528.22 english |
Clinical Study Number | 528.23 |
---|---|
Study Indication | Healthy |
Product | Terbogrel |
Generic Name | Terbogrel |
Lab Code | |
Clinical Phase | I |
Study Title |
Influence of oral doses of 75 mg Clopidogrel on the pharmacodynamics and safety of oral doses of 100 mg Terbogrel bid over 8 days in healthy male subjects. An intra-individual, open trial. |
Study Document | Trial synopsis 528.23_CO english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.